Novel TKI Plus Chemo Dramatically Shrank Advanced Head & Neck Tumors
April 25, 2018
AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial.
Anne Landry
Late Diagnosis: Cause of Poorer Survival in Alcohol-Related Liver Cancer?
April 23, 2018
Patients with alcohol-related HCC had worse OS than other HCC patients, mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis.
ACS Nutrition, Activity Guidelines Boost Survival in Stage III CRC
April 17, 2018
Stage III colon cancer patients adhering to ACS Nutrition and Physical Activity Guidelines for Cancer Survivors after diagnosis had a 42% lower risk of death.
Differential Methylation in CITED4: Bladder Cancer Risk Biomarker?
March 20, 2018
Differential methylation in CITED4, as measured in blood, appears to be a promising marker of bladder cancer susceptibility in women.
Minimum Legal Sale Age for Tobacco, E-Cigarettes Jumps From 18 to 21 in NYC
November 21, 2013
On November 19, New York City Mayor Michael Bloomberg signed legislation (Tobacco 21 [Intro 250-A]) making New York the first major city to ban the sale of cigarettes, certain tobacco products, and e-cigarettes to anyone under 21 years of age, up from age 18.
Post-Orchiectomy Surveillance Is Sufficient for Men With Stage I Seminoma
August 10, 2013
At the 2013 ASCO meeting, investigators of a large Danish study have concluded that surveillance alone following surgery for stage I seminoma is sufficient, sparing patients in this setting from the unnecessary expense and associated toxicities of chemotherapy and radiation treatment.
Use of Surveillance CT Scans to Detect DLBCL Relapse
July 26, 2013
A study from the Mayo Clinic/University of Iowa assessing the use of surveillance CT scans to detect DLBCL relapses found that the majority of relapses occurred outside of regularly scheduled visits and concluded that it is important to educate patients to be more alert to signs and symptoms of relapse.
ASCO: Cetuximab Ups Survival Over Bevacizumab in Colorectal Cancer
June 15, 2013
Results from the German AIO KRK-0306 study, FIRE-3, show that the addition of cetuximab (Erbitux) to chemotherapy rather than bevacizumab (Avastin) increased overall survival by nearly 4 months in patients with KRAS wild-type metastatic colorectal cancer.
ASCO: Sorafenib Slows Progression in Advanced Thyroid Cancer
June 10, 2013
Data presented at ASCO from the phase III DECISION trial showed treatment with the TKI sorafenib (Nexavar) delayed disease progression by 5 months in patients with metastatic differentiated thyroid cancer that had progressed on radioactive iodine.
ASCO: Avastin Improves Survival in Advanced Cervical Cancer
June 7, 2013
Results from the phase III GOG 240 trial, presented at ASCO, showed the addition of bevacizumab (Avastin) to standard chemotherapy improved overall survival by nearly 4 months in women with advanced or relapsed cervical cancer.
